Search by Drug Name or NDC

    NDC 61314-0454-20 HYRIMOZ 80 mg/.8mL Details

    HYRIMOZ 80 mg/.8mL

    HYRIMOZ is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sandoz Inc. The primary component is ADALIMUMAB.

    Product Information

    NDC 61314-0454
    Product ID 61314-454_5f7d6cf0-6300-4c73-a848-e9da6adf1680
    Associated GPIs
    GCN Sequence Number 084553
    GCN Sequence Number Description adalimumab-adaz PEN INJCTR 80MG/0.8ML SUBCUT
    HIC3 S2J
    HIC3 Description ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR
    GCN 53887
    HICL Sequence Number 045444
    HICL Sequence Number Description ADALIMUMAB-ADAZ
    Brand/Generic Brand
    Proprietary Name HYRIMOZ
    Proprietary Name Suffix n/a
    Non-Proprietary Name adalimumab-adaz
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 80
    Active Ingredient Units mg/.8mL
    Substance Name ADALIMUMAB
    Labeler Name Sandoz Inc
    Pharmaceutical Class Antibodies, Monoclonal [CS], Tumor Necrosis Factor Blocker [EPC], Tumor Necrosis Factor Receptor Blocking Activity [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761071
    Listing Certified Through 2024-12-31

    Package

    NDC 61314-0454-20 (61314045420)

    NDC Package Code 61314-454-20
    Billing NDC 61314045420
    Package 2 SYRINGE in 1 CARTON (61314-454-20) / .8 mL in 1 SYRINGE
    Marketing Start Date 2023-07-01
    NDC Exclude Flag N
    Pricing Information N/A